What is the clinical treatment effect of Teclistamab-cqyv?

Teritusumab (Teclistamab-cqyv) has shown promising therapeutic effects in multiple international clinical studies, especially for patients with multiple myeloma who have failed to respond to standard treatment options. The most representative study globally is the MajesTEC-1 clinical trial, a large-scale multi-center study in patients with relapsed or refractory multiple myeloma.

In this study, patients received multiple lines of therapy, including immunomodulators (such as lenalidomide), proteasome inhibitors (such as bortezomib), and anti-CD38 monoclonal antibodies (such as daratumumab). These patients have lost sensitivity to traditional treatments and are in a state where no drugs are available.

After receiving teritusumab treatment on this basis, the objective response rate (ORR) is as high as more than 60%, of which the complete response rate is close to 30%. More importantly, the median duration of response was more than 12 months, demonstrating durable anti-tumor activity.

It is important to note that treatment with teritusumab is not without risks. The most common adverse reaction is cytokine release syndrome (CRS), with an incidence rate of more than 70%. However, most CRS is grade 1-2 and can be effectively controlled with standard supportive care (such as tocilizumab). Other side effects include anemia, neutropenia, infection, etc., which need to be used under close supervision by a doctor.

Overall, teritusumab provides new treatment hope for patients with multiple myeloma, especially those at high risk of relapse despite having been treated with three major classes of drugs. Its treatment mechanism is novel, the response rate is high, and the duration is long, making it a milestone in the field of immunotherapy for multiple myeloma. In the future, as the drug is gradually approved and marketed in more countries, more patients are expected to benefit from it.

Reference materials:https://www.tecvayli.com/